台灣醣聯生技醫藥股份有限公司 Approved
最後更新時間 2025/06/16 , 10:38 AM
最後更新時間 2025/06/16 , 10:38 AM
負責人
Zhang,Dong-Xuan
統一編號
12683520
成立日期
2001/02/01
資本額
NT$2,000,000,000
實收資本額
NT$1,086,401,330
股票代號
4168
電話
02-26974168
地址
8F, No. 97, Sec. 1, Sintai 5th Rd., Xizhi Dist., New Taipei City, 221, Taiwan
董監事
姓名 職稱 持有股份 代表法人
Zhang,Dong-Xuan Chairman 3.97%
TAIWAN ADVANCE BIO-PHARMACEUTICAL INC. Director 2.87%
Su,Xiu-E Director 2.03%
Yang,Mei-Jun Director 0.58%
Cai,Ling-Jun Independent Director 0.00%
Lin,Jiong-Sen Independent Director 0.00%
Xu,Guang-Yang Independent Director 0.00%
營業項目
  • Research and Experimental Development on Natural Sciences and Engineering(721000)
  • Wholesale on a Fee or Contract Basis(451099)
  • Wholesale of Other Machinery and Equipment(464918)
  • Management Consultancy Activities(702099)
  • 公司歷程
  • Change Capital to 2,000,000,000
    2019/08/01
  • Change Capital to 1,000,000,000
    2011/09/14
  • 員工人數
    財務報表
    項目 2025 2024 2023
    Operating income 13,569 14,701 2,542
    Operating cost 1,833 7,380 1,547
    Profit (loss) of initial recognition of biological asset and agricultural products - - -
    Profit (loss) on changes in fair value less costs to sell of biological asset for current period - - -
    Operating gross profit (loss) 11,736 7,321 995
    Unrealized profit (loss) on sales of goods - - -
    Realized profit (loss) on sales of goods - - -
    Operating gross profit (loss), net 11,736 7,321 995
    Operating expenses 63,638 253,437 260,859
    Other gain (loss), net - - -
    Operating profit (loss) -51,902 -246,116 -259,864
    Non-operating income and expenses 7,424 16,435 96,147
    Net profit (loss) before tax -44,478 -229,681 -163,717
    Income tax expense (benefits) 0 24 14,645
    Net profit (loss) of ongoing business for the current period -44,478 -229,705 -178,362
    Profit (loss) of closed units - - -
    Profit (loss) of non-jointly controlled equity before merger - - -
    Net profit (loss) for the current period -44,478 -229,705 -178,362
    Other comprehensive profit (loss), net 305 -236 -654
    Comprehensive net profit and loss of non-jointly controlled equity before merger - - -
    Total comprehensive profit and loss for the current period -44,173 -229,941 -179,016
    Net profit (loss) attributable to owners of parent company -44,478 -229,705 -178,362
    Net profit (loss) form equity attributable to former owner of business combination under common control - - -
    Net profit (loss) attributable to non-controlling interests - - -
    Comprehensive profit (loss) attributable to owners of parent company -44,173 -229,941 -179,016
    Comprehensive profit (loss) form equity attributable to former owner of business combination under common control - - -
    Comprehensive profit (loss) attributable to non-controlling interests - - -
    Basic earnings per share (yuan) 0 -2 -1
    項目 2025 2024 2023
    Net cash inflow (outflow) from operating activities -44,347 -221,968 -183,922
    Net cash inflows (outflows) from investing activities 34,373 181,997 257,925
    Net cash inflow (outflow) from financing activities 16 12 -6,723
    Effect of Exchange Rate Changes on Cash and Cash Equivalents - - -
    Increase (decrease) in cash and cash equivalents in the current period -9,958 -39,959 67,280
    Beginning balance of cash and cash equivalents 109,508 149,467 82,187
    Ending balance of cash and cash equivalents 99,550 109,508 149,467
    項目 2025 2024 2023
    Current asset 467,382 481,202 718,333
    Non-current asset 828,208 835,278 834,481
    Total asset 1,295,590 1,316,480 1,552,814
    Current liability 287,932 264,635 270,583
    Non-current liability 5,357 5,371 5,816
    Total liability 293,289 270,006 276,399
    share capital 1,082,081 1,086,401 1,086,401
    Equity - secruity token - - -
    capital reserve 201,066 196,746 374,857
    retained earning -273,846 -229,368 -178,111
    Other equity -7,000 -7,305 -6,732
    Treasury stock - - -
    Total equity attributable to owners of parent company 1,002,301 1,046,474 1,276,415
    Equity attributable to former owner of business combination under common control - - -
    Equity attributable to non-controlling interest before business merger under common control - - -
    Non-controlling interests - - -
    Total Equity 1,002,301 1,046,474 1,276,415
    Share capital awaiting retirement (unit: share) 432,000 0 0
    Issued shares of advance equity (unit: shares) 0 0 0
    Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) 0 0 0
    Net asset value per share 9 9 11
    動產抵押
    下載完整報告查看完整數據
    案件類別 債務人名稱 債務人統編 契約啟始日期 契約終止日期 抵押權人名稱 抵押權人統編 擔保債權金額
    選舉收入(政治獻金)
    收入名稱 收入金額
    總收入金額
    選舉支出(政治獻金)
    支出名稱 支出金額
    總支出金額
    標案拒往
    機關名稱 生效日期 截止日期
    進出口資料
    下載完整報告查看完整數據
    年份 月份 總進口實績(美金) 總出口實績(美金)
    商標
  • gnx GLYCONEX INC.
  • GNX
  • 專利
    政府標案
    標案名稱 機關名稱 決標日期 決標金額 是否得標
    裁判書查詢
  • Payment order
    2022, 2023
  • 勞權違規
    日期 違反法規法條 罰鍰金額
    污染源裁處
    污染類別 裁處時間 裁處機關 裁處金額 違反事實 違反法令 裁處書字號 裁處理由及法令 公司地址
    本頁內所載之資料,所載資料之完整性、即時性和正確性仍應以資料來源單位為準。
    公司一有新動態,我們馬上通知你,追蹤公司讓你不錯過任何更新。